SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinomas Clinical Trial

Official title:

Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05022654
• Other study ID #: SI-B001_207
• Status: Recruiting
• Phase: Phase 2
• Start date: December 13, 2021
• Est. completion date: April 2024

Study information

• Verified date: January 2024
• Source: Sichuan Baili Pharmaceutical Co., Ltd.
• Contact: Hai Zhu
• Phone: +8613980051002
• Email: zhuhai[@]baili-pharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntarily sign the informed consent and follow the requirements of the protocol;

2. Male or female, age: =18 years and =75 years;

3. Expected survival time =3 months;

4. Locally advanced esophageal squamous cell carcinoma confirmed histologically or pathologically as recurrent or metastatic or without indications of radical local treatment;

5. Patients who failed or were intolerant to first-line anti-PD-1 (L1) monoclonal antibody plus platinum-based chemotherapy

6. Agree to provide archived tumor tissue specimens of primary or metastatic lesion (4 surgical specimens (thickness 5µm) without staining section (anti-removal);6 unstained sections (anti-removal) surgical specimens (thickness 10µm) or fresh tissue samples, if the patient cannot provide, can be included after the investigator's judgment;

7. There must be at least one measurable lesion conforming to the RECIST V1.1 definition. Tumor lesion located in the area of previous radiotherapy or other local and regional treatment sites is generally not a measurable lesion unless there is definite progression of the lesion or the lesion persists three months after radiotherapy;

8. Physical fitness ECOG score of 0 or 1;

9. Toxicity from previous antitumor therapy has returned to =1 as defined by NCI-CTCAE V5.0 (except for toxicity that the investigators determined to be of no safety risk, such as hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism after hormone replacement therapy);

10. Organ function levels must meet the following requirements and meet the following standards:

A) Bone marrow function: absolute neutrophil count (ANC) =1.5×10^9/L, platelet count =90×10^9/L, hemoglobin =90 g/L; B) Liver function: Total bilirubin TBIL=1.5×ULN (total bilirubin =3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver metastasis), AST and ALT =2.5×ULN in patients without liver metastasis, AST and ALT =5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) =1.5×ULN, or creatinine clearance (Ccr) =50 mL/min (according to Cockcroft and Gault formula); D) Urine routine / 24-hour protein quantification: qualitative urine protein =1+ (if qualitative urine protein =2+, 24 hours < 1g can be included); E) Cardiac function: left ventricular ejection fraction =50%; F) Coagulation function: International standardized ratio (INR) =1.5×ULN, and activated partial thrombin time (APTT) =1.5×ULN;

11. Eligible patients (male and female) who are fertile must agree to use a reliable contraceptive method (hormonal or barrier method or abstinence, etc.) with their partner during the trial and for at least 6 months after the last medication;Women of childbearing age must have a negative blood or urine pregnancy test within 7 days prior to the first use of the study drug.

Exclusion Criteria:

1. Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug, except for the following:

Oral fluorouracil and small molecule targeted drugs were used within 2 weeks before the first administration of the study drug or within 5 half-lives of the drug; The traditional Chinese medicines with anti-tumor indications were within 2 weeks before the first use of the study drug;

2. Patients with esophageal fistula;

3. Received an unmarketed clinical investigational drug or treatment within 4 weeks prior to initial use of the investigational drug;

4. Had major organ surgery (excluding needle biopsy, tracheotomy, gastrostomy, etc.) or had significant trauma within 4 weeks prior to the first use of study drugs, or needed to undergo elective surgery during the trial;

5. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation;

6. A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade iii atrioventricular block, etc; In the resting state, QT interval was prolonged (QTc > 450 msec in men or QTc > 470 msec in women); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 or higher cardio-cerebrovascular events within 6 months prior to the first administration; New York Heart Association (NYHA) heart function grade =II heart failure;

7. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus, inflammatory bowel disease, etc., except type I diabetes, hypothyroidism that can be controlled only with replacement therapy, and skin diseases that do not require systemic treatment;

8. Patients with a history of other malignant tumors and signs of recurrence and metastasis within 1 year before the first administration;

9. Poorly controlled hypertension (systolic blood pressure & GT;150 mmHg or diastolic pressure >100 mmHg);

10. Pulmonary disease of grade 3 or higher defined by CTCAE V5.0;Patients with past or present interstitial lung disease (ILD);

11. Cerebral parenchymal or meningeal metastases with clinical symptoms were not suitable for inclusion.

12. Previous use of anti-EGFR antibody drug therapy;

13. There are known allergic contraindications to any excipients of SI-B001 or irinotecan;

14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;

15. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, septicemia, etc;'

16. Pregnant or lactating women;

17. Persons with mental disorders or poor compliance;

18. The investigator considers that the subject has a history of other serious systemic diseases or other reasons to be unsuitable for this clinical study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinomas

Intervention

Drug:
• SI-B001
Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
• Irinotecan
The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.

Locations

Country	Name	City	State
China	Anyang Cancer Hospital of Henan Province	Anyang	Henan
China	Beijing Cancer Hostital	Beijing	Beijing
China	The First Affiliated Hospital of Henan University of Science and Technology	Luoyang	Henan
China	Suining Central Hospital	Suining	Sichuan
China	Shanxi Cancer Hospital	Taiyuan	Shanxi
China	Xuzhou Central Hospital	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Baili Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	objective response rate	Up to approximately 24 months
Primary	Optimal combination dose (only IIa)	Optimal combination dose of SI-B001 with irinotecan(only IIa)	Up to approximately 24 months
Secondary	PFS	Progression-Free-Survival	Up to approximately 24 months
Secondary	DCR	Disease-control rate	Up to approximately 24 months
Secondary	DOR	Duration of Response	Up to approximately 24 months
Secondary	OS	Overall Survival	Up to approximately 24 months
Secondary	TEAE	Treatment Emergent Adverse Events	Up to approximately 24 months
Secondary	Cmax	Maximum serum concentration	Up to approximately 24 months
Secondary	Tmax	Time to maximum serum concentration	Up to approximately 24 months
Secondary	Ctrough	Minimum serum concentration	Up to approximately 24 months
Secondary	ADA	anti-SI-B001 antibody	Up to approximately 24 months